These results, together with a recent finding that BTN3A1 can significantly inhibit the antitumor effect of αβ T cell by abrogating TCR activation in ovarian cancer,[48] are suggestive of BTN3A1 as a novel checkpoint molecule and an alternative function of Vγ9Vδ2 T cell as a “cellular ICI”. This evidence concerns the gene BTN3A1 and ovarian cancer.